Evidence map›Paper›PMID 30952644›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.

Omar El Charif, Brandon Mapes, Matthew R Trendowski, Heather E Wheeler, Claudia Wing, Paul C Dinh, Robert D Frisina, Darren R Feldman, Robert J Hamilton, David J Vaughn and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  9. Article
  10. Article
  11. Testicular cancer survivorship: Long-term toxicity and management.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  18. Noise: Acoustic Trauma and Tinnitus, the US Military Experience.Otolaryngologic clinics of North America · 2020
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Omar El CharifDepartment of Medicine, University of Chicago, Chicago, Illinois.
Brandon MapesDepartment of Medicine, University of Chicago, Chicago, Illinois.
Matthew R TrendowskiDepartment of Medicine, University of Chicago, Chicago, Illinois.
Heather E WheelerDepartments of Biology and Computer Science, Loyola University Chicago, Chicago, Illinois.
Claudia WingDepartment of Medicine, University of Chicago, Chicago, Illinois.
Paul C DinhDepartment of Medical Oncology, Indiana University, Indianapolis, Indiana.
Robert D FrisinaDepartments of Medical and Chemical & Biomolecular Engineering and Communication Sciences & Disorders, Global Center for Hearing and Speech Research, University of South Florida, Tampa, Florida.
Darren R FeldmanDepartment of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Robert J HamiltonDepartment of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
David J VaughnDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Chunkit FungJ.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Christian KollmannsbergerDivision of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
Taisei MushirodaRIKEN Center for Integrative Medical Science, Yokohama, Japan.
Michiaki KuboRIKEN Center for Integrative Medical Science, Yokohama, Japan.
Eric R GamazonClare Hall, University of Cambridge, Cambridge, United Kingdom.
Nancy J CoxVanderbilt University Medical Center, Nashville, Tennessee.
Robert HuddartRoyal Marsden Hospital, London, United Kingdom.
Shirin Ardeshir-Rouhani-FardDepartment of Medical Oncology, Indiana University, Indianapolis, Indiana.
Patrick MonahanDepartment of Medical Oncology, Indiana University, Indianapolis, Indiana.
Sophie D FossaDepartment of Oncology, Oslo University Hospital, Radiumhospital, Oslo, Norway.
Lawrence H EinhornDepartment of Medical Oncology, Indiana University, Indianapolis, Indiana.
Lois B TravisDepartment of Medical Oncology, Indiana University, Indianapolis, Indiana. edolan@medicine.bsd.uchicago.edu lbtravis@iu.edu.
M Eileen DolanDepartment of Medicine, University of Chicago, Chicago, Illinois. edolan@medicine.bsd.uchicago.edu lbtravis@iu.edu.
University of Chicago · USVanderbilt University Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
PHARMACOGENETICS OF MEMBRANE TRANSPORTERSU01GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2000 to 2009
$29.2M
Pharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2010 to 2014
$16.3M
Genetic Susceptibility and Biomarkers of Platinum-related ToxicitiesR01CA157823 · NCI · UNIVERSITY OF ROCHESTER · PI TRAVIS, LOIS B. · 2012 to 2025
$11.2M
PGRN Administrative Coordination Hub, ACH (PGRN)U24GM115370 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M, JOHNSON, GRAHAM T. · 2015 to 2019
$2.7M
Department of HealthNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA157823NIGMS NIH HHS U01 GM061390NIGMS NIH HHS U19 GM061390NIGMS NIH HHS U24 GM115370
6 · The paper itself

Abstract

purposeCisplatin, a commonly used chemotherapeutic, results in tinnitus, the phantom perception of sound. Our purpose was to identify the clinical and genetic determinants of tinnitus among testicular cancer survivors (TCS) following cisplatin-based chemotherapy. EXPERIMENTAL

designTCS (

resultsCisplatin-induced tinnitus (CisIT) significantly associated with age at diagnosis (

conclusionsCisIT associated with several neuro-otological symptoms, increased use of psychotropic medication, and poorer health.

Indexed as

Disease SusceptibilityGenome-Wide Association StudyAdultAgedAntineoplastic AgentsCase-Control StudiesCell Line, TumorCell SurvivalCisplatinGenetic Predisposition to DiseaseHumansMiddle AgedOtotoxicityPolymorphism, Single NucleotideRisk FactorsSelf ReportAntineoplastic AgentsCisplatin

Identifiers

PMID30952644
PMCPMC6903403
OpenAlexW2932040760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.